SCHEMBL22718246

SCHEMBL22718246

CNS(=O)(=O)c1cnc(N[C@@H](C)c2ccccc2)c(-c2cn(C)cn2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TEAD1 P28347 1/20 0.43
▸ YAP1 P46937 1/20 0.43
▸ BRD4 O60885 1/20 0.42
▸ LDHA P00338 2/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ EGFR P00533 6/20 0.38
▸ ATP1A1 P05023 5/20 0.37
▸ ATP1B1 P05026 5/20 0.37
▸ ATP1A3 P13637 5/20 0.37
▸ ATP1B2 P14415 5/20 0.37
▸ ATP1A2 P50993 5/20 0.37
▸ ATP1B3 P54709 5/20 0.37
▸ FXYD2 P54710 5/20 0.37
▸ ATP1A4 Q13733 5/20 0.37
▸ SYK P43405 1/20 0.37
▸ GALR3 O60755 1/20 0.36
▸ NR2F2 P24468 1/20 0.36
▸ LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22718228 1.00 TEAD1 (0.43) TEAD1YAP1BRD4LDHAALDH1A1
SCHEMBL22718231 1.00 TEAD1 (0.43) TEAD1YAP1BRD4LDHAALDH1A1
SCHEMBL24496110 0.87 TEAD1 (0.58) TEAD1YAP1BRD4EGFRATP1A1
SCHEMBL29648323 0.87 TEAD1 (0.58) TEAD1YAP1BRD4EGFRATP1A1
SCHEMBL22718030 0.84 TEAD1 (0.56) TEAD1YAP1ALDH1A1EGFRSYK
SCHEMBL29438864 0.84 TEAD1 (0.56) TEAD1YAP1ALDH1A1EGFRSYK
SCHEMBL22718032 0.84 TEAD1 (0.56) TEAD1YAP1ALDH1A1EGFRSYK
SCHEMBL22718117 0.84 TEAD1 (0.56) TEAD1YAP1ALDH1A1EGFRSYK
SCHEMBL29438900 0.84 TEAD1 (0.56) TEAD1YAP1ALDH1A1EGFRSYK
SCHEMBL29438851 0.84 TEAD1 (0.56) TEAD1YAP1ALDH1A1EGFRSYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577208-B2 TEAD inhibitors and uses thereof EHE Foundation (US) 2026-03-17 — — US disclosed
CN-119954725-A TEAD inhibitors and uses thereof 医肯纳肿瘤学公司 2025-05-09 — — CN disclosed
CN-114466839-B TEAD inhibitors and uses thereof 医肯纳肿瘤学公司 2025-01-07 — — CN disclosed
WO-2024092116-A1 COMBINATION OF TEAD INHIBITORS AND EGFR INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2024-05-02 — — WO disclosed
US-20240083854-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2024-03-14 — — US disclosed
US-11760728-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2023-09-19 — — US disclosed
US-11760728-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2023-09-19 — — US disclosed
WO-2022187518-A1 SUBSTITUTED 4-PIPERIDINYL-IMIDAZO[4,5-B]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS Ikena Oncology, Inc. (US) 2022-09-09 — — WO disclosed
US-20220251048-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2022-08-11 — — US disclosed
WO-2022120355-A1 TEAD DEGRADERS AND USES THEREOF Ikena Oncology, Inc. (US) 2022-06-09 — — WO disclosed
EP-3976194-A2 TEAD INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2022-04-06 — — EP disclosed
US-11274082-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-03-15 — — US disclosed
US-11274082-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-03-15 — — US disclosed
US-20200407327-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2020-12-31 — — US disclosed
US-20200407327-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2020-12-31 — — US disclosed
WO-2020243415-A2 TEAD INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2020-12-03 — — WO disclosed
WO-2020243415-A2 TEAD INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2020-12-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220251048-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 TEAD1 4/4885YAP1 111/4885BRD4 155/4885
US-11274082-B2 Tead inhibitors and uses thereof TEAD2, TEAD3, TEAD4 TEAD1 4/4885YAP1 111/4885BRD4 155/4885
US-20240083854-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 TEAD1 4/4885YAP1 111/4885BRD4 155/4885
US-11760728-B2 Tead inhibitors and uses thereof TEAD2, TEAD3, TEAD4 TEAD1 4/4885YAP1 111/4885BRD4 155/4885
US-12577208-B2 TEAD inhibitors and uses thereof BRCA1, BRAF, MEN1 TEAD1 7/4885YAP1 13/4885BRD4 144/4885
US-20200407327-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 TEAD1 4/4885YAP1 111/4885BRD4 155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback